Stock Price & Analysis

Based on current analysis, ALKS stock presents a mixed outlook. While some analysts maintain a Strong Buy rating with upside potential, insider selling and mixed institutional sentiment suggest caution.

Price Prediction for ALKS Stock in 2025

Based on strong Q4 earnings, a promising pipeline, and analyst consensus, ALKS stock is predicted to reach $39 in 2025, driven by its advancing orexin program and potential long-term growth opportunities. The stock currently trades at $33.85, with an average analyst price target of $39.30, indicating an 18% upside potential. However, risks include near-term earnings pressure and competitive narcolepsy market dynamics.

The S1 support level for ALKS Stock is $33.27 ,The R1 resistant level for ALKS Stock is $35.24.

As of the end of day on 2025-03-24, the price of ALKS Stock was $34.89.

The target price for ALKS Stock according to analyst rating is 38.42, with the highest price target at 46.00 and the lowest at 30.00. Analysts have a Moderate Buy rating on ALKS Stock overall.

The market cap of ALKS is $5.7B.

Analysis and Insights

Valuation Metrics:

Alkermes (ALKS) currently shows mixed valuation signals. The stock's PE ratio of 13.08 for Q4 2024 and EV/EBITDA of 8.69 suggest moderate valuation levels. However, the price-to-sales ratio of 3.13 indicates a premium relative to its revenue generation.

Market Sentiment:

Analysts have a wide range of price targets, from $21.00 to $43.00, with a consensus of $39.30. This suggests uncertainty about the stock's future potential. The stock recently surpassed the average analyst target of $34.38, trading at $36.00, which may indicate it is approaching overvalued territory.

Insider and Institutional Activity:

Insiders have sold shares recently, with no purchases in the last six months. Institutions are also divided, with more sellers than buyers in the latest quarter, signaling mixed sentiment.

Conclusion:

While ALKS is not severely overvalued, its current price near the higher end of analyst targets and insider selling activity suggest caution. Investors should consider whether the stock's fundamentals justify its premium.

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Based on strong earnings, growing proprietary products, and a promising pipeline, ALKS stock could reach $60 by 2030. Its robust financial position and pipeline, including ALKS 2680, support long-term growth.

ALKS has a total of 2100 employees.